1. Home
  2. Browse
  3. HRA003889
HRA003889
   HRA003889.xlsx
Title:
High throughput sequencing data of FLT3-ITD AML
Release date:
2023-02-02
Description:
In order to study the mechanism of FLT3-ITD AML resistance to FLT3, we detected the gene mutation and expression of AML 12 patients with FLT3-ITD by NGS
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA012927
Study type:
Disease Study
Disease name:
acute myeloid leukemia
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC001933
DAC name:
Lijia Group Bioinformatics Core
Contact person:
Luo Guanghao
Email:
guangho2743@foxmail.com
Description:
Professor Li and his group have established multi-targets screening, multi-function confirmation, and multi-index efficacy evaluation system for diabetes and cancer drug discovery, built up enzyme family based multi-target integrated high throughput screening platform, in line with international standards. Up to now, his team has completed over million data points in drug screening and discovered hundreds of bioactive compounds. As one of the major inventors, Professor Li led four drug candidates targeting metabolic diseases and two drug candidates targeting tumor with independent intellectual property rights, of which pre-clinical studies are under way. Among this, one of the drug candidates has been successfully transferred to a local pharmaceutical company and move forward cooperatively.
Individuals & samples
Files
Request Data
Submitter:   Li Jia / jli@simm.ac.cn
Organization:   Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Submission date:   2023-01-31
Requests:   2